IZBrunch brings together decision-makers from IZB startups, scientists, and other key players in the life sciences ecosystem around the Martinsried/Großhadern campus. The IZB hosts this event once a quarter at the Faculty Club.
Each gathering focuses on a current topic in biotechnology, medicine, and the life sciences. Topics range from the use of artificial intelligence in drug development and theranostics in oncology, to the use of yeast in biotechnology. Two speakers explore the chosen topic from different perspectives.
Following the presentations, a business lunch offers the opportunity to deepen the conversation. In this way, IZBrunch combines expert insights with in-person networking, creating a space to forge new connections within the Munich biotech community.
Attendance is limited to 70 people. Advance registration is required.
Registration: IZBrunch@izb-online.de
Please note: Attendance is strictly limited to those with a confirmed registration.
Who attends?
Faculty Club members, directors and research group leaders of the Max Planck Institutes, LMU professors, managing directors and board members of the IZB companies, and executives of the Martinsried/Großhadern campus.
Format:
Face2Face event with keynote speeches (15 min.) plus Q&A followed by business lunch
Time:
10:45 a.m. to 1 p.m.
Location:
Restaurant SEVEN AND MORE
in the IZB Residence CAMPUS AT HOME
Am Klopferspitz 21
82152 Planegg/Martinsried
Registration: koehler@izb-online.de
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
Prof. Dr. Olivia Merkel
Chair Holder and Deputy Director, Department of Pharmacy, LMU Faculty of Chemistry and Pharmacy
RNA therapeutics hold enormous potential for treating pulmonary diseases, but getting the right RNA into the right cells remains a major challenge. This talk will show how tuning nanoparticle structure and targeting can translate into functional gene silencing in the diseased lung and present new data pushing these systems toward preclinical therapeutic applications.
Dr. Benjamin Winkeljann
Co-founder and CEO of IZB-based start-up RNhale
While advances in nanomedicine are improving how RNA reaches target cells, successful pulmonary therapies also depend on how these medicines are delivered to the lung. This talk will explore the fundamentals of inhaled drug delivery, including aerosol generation, formulation design, particle engineering, and inhaler technologies, and present recent developments supporting the translation of RNA therapeutics into inhaled medicines.
Name (EN)
Function of Speakers
Topic:
Description of topic
Christian Gnam
Managing Director, IZB
Christian Gnam
Managing Director, IZB
Topic:
Description of topic
